Abstract
A defect in cerebral energy production due to dysfunction of the mitochondrial electron transport system (ETS) has been postulated to be important in the pathogenesis of Parkinson Disease (PD). However, direct in vivo measurements of cerebral mitochondrial function are scant and inconsistent. We directly investigated cerebral mitochondrial function in vivo with positron emission tomography (PET) in 12 patients with early, never-medicated PD and 12 age-matched normal controls by combined measurements of the cerebral metabolic rate of oxygen (CMRO2) and the cerebral metabolic rate of glucose (CMRglc). Instead of the decrease in CMRO2 and CMRO2/CMRglc molar ratio characteristic of defects in mitochondrial oxidative metabolism, there was a statistically significant 24% general increase in CMRO2 and no change in CMRO2/CMRglc. Since PD symptoms were already manifest, reduced oxidative activity of the mitochondrial ETS cannot be a primary mechanism of neuronal death in early PD. This increase in metabolism could reflect the increased energy requirements of an injured brain or an uncoupling of ATP production from oxidation in the terminal stage of oxidative phosphorylation. Which is the case in early PD and whether these metabolic abnormalities are important in the pathogenesis of PD will require further study.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci 7:207–219
Berding G, Odin P, Brooks DJ, Nikkhah G, Matthies C, Peschel T, Shing M, Kolbe H, van Den Hoff J, Fricke H, Dengler R, Samii M, Knapp WH (2001) Resting regional cerebral glucose metabolism in advanced Parkinson’s disease studied in the off and on conditions. Mov Disord 16:1014–1022
Borghammer P, Cumming P, Aanerud J, Förster S, Gjedde A (2009) Subcortical elevation of metabolism in Parkinson’s disease—a critical reappraisal in the context of global mean normalization. Neuroimage 47:1514–1521
Brierley JB, Prior PF, Calverley J, Brown AW (1977) Cyanide intoxication in Macaca mulatta. Physiological and neuropathological aspects. J Neurol Sci 31:133–157
Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E (1993) Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson’s disease. Ann Neurol 33:518–527
Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S (1994) The metabolic topography of Parkinsonism. J Cereb Blood Flow Metab 14:783–801
Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Chaly T, Belakhlef A, Mandel F, Przedborski S, Fahn S (1995) Early differential diagnosis of Parkinson’s disease with 18F-fluorodeoxyglucose and positron emission tomography. Neurology 45:1995–2004
Frackowiak RSJ, Herold S, Petty RK, Morgan-Hughes JA (1988) The cerebral metabolism of glucose of oxygen measured with positron tomography in patients with mitochrondrial diseases. Brain 111:1009–1024
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442
Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26:5256–5264
Kuhl DE, Metter EJ, Riege WH (1984) Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the [18F]fluorodeoxyglucose method. Ann Neurol 15:419–424
Leenders KL, Wolfson L, Gibbs JM, Wise RJ, Causon R, Jones T, Legg NJ (1985) The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson’s disease. Brain 108:171–191
Martin WR, Beckman JH, Calne DB, Adam MJ, Harrop R, Rogers JG, Ruth TJ, Sayre CI, Pate BD (1984) Cerebral glucose metabolism in Parkinson’s disease. Can J Neurol Sci 11:169–173
Mohr E, Mann UM, Miletich RS, Sampson M, Goldberg TE, Grimes JD, Chase TN (1992) Neuropsychological and glucose metabolic profiles in asymmetric Parkinson’s disease. Can J Neurol Sci 19:163–169
Patel JR, Brewer GJ (2003) Age-related changes in neuronal glucose uptake in response to glutamate and beta-amyloid. J Neurosci Res 72:527–536
Piert M, Koeppe RA, Giordani B, Minoshima S, Kuhl DE (1996) Determination of regional rate constants from dynamic FDG-PET studies in Parkinson’s disease. J Nucl Med 37:1115–1122
Powers WJ, Videen TO, Markham J, Black KJ, Golchin N, Perlmutter JS (2008) Cerebral mitochondrial metabolism in early Parkinson’s disease. J Cereb Blood Flow Metab 28:1754–1760
Rango M, Bonifati C, Bresolin N (2006) Parkinson’s disease and brain mitochondrial dysfunction: a functional phosphorus magnetic resonance spectroscopy study. J Cereb Blood Flow Metab 26:283–290
Rougemont D, Baron JC, Collard P, Bustany P, Comar D, Agid Y (1984) Local cerebral glucose utilisation in treated and untreated patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 47:824–830
Schapira AH (1994) Evidence for mitochondrial dysfunction in Parkinson’s disease—a critical appraisal. Mov Disord 9:125–138
Tretter L, Adam-Vizi V (2007) Uncoupling is without an effect on the production of reactive oxygen species by in situ synaptic mitochondria. J Neurochem 103:1864–1871
Wolfson LI, Leenders KL, Brown LL, Jones T (1985) Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson’s disease. Neurology 35:1399–1405
Wooten GF, Collins RC (1981) Metabolic effects of unilateral lesion of the substantia nigra. J Neurosci 1:285–291
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Powers, W.J. PET studies of cerebral metabolism in Parkinson Disease. J Bioenerg Biomembr 41, 505–508 (2009). https://doi.org/10.1007/s10863-009-9251-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10863-009-9251-5